The Quantellect read.As of Nov 19, 2026, 7 active firms cover Capricor Therapeutics Inc: 5 rate it Buy or better, 2 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $21.00 to $60.00 (about 2.9x), a sign of real disagreement on valuation. The average target of $39.67 sits 394% above the current $8.04. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.46 next quarter toward $-1.43 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 active firms
Buy
Strong Buy00%
Buy571%
Neutral229%
Sell00%
Strong Sell00%
Based on 7 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$39.67
+393.7% upside
Average target across 6 active firms as of Nov 19, 2026 vs $8.04 current
Highest Target$60.00
Average Target$39.67
Lowest Target$21.00
Detailed analyst forecasts for CAPR
Showing 1–7 of 7 named analysts shown · 7 active firms in the rating projection
As of Nov 19, 2026, 5 of 7 active firms rate CAPR a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
CAPR EPS & revenue forecast
EPS · NEXT QUARTER
$-0.46
Range $-0.61 – $-0.26 · 4 analysts
Next period, 4 analysts expect Capricor Therapeutics Inc to earn $-0.46 a share (range $-0.61 – $-0.26), versus — a year earlier. Full-year consensus is $-2.45, growing to $-1.43 the year after.
REVENUE · NEXT QUARTER
$7.6M
Range $0 – $18.7M · 4 analysts
Revenue is expected to reach $7.6M (range $0 – $18.7M). Full-year consensus is $13.3M, rising to $66.4M next year.
Top analysts covering Capricor Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CAPR.
#1
Kristen Kluska
Cantor Fitzgerald · Rank #232
Buy
$28.00+248.5% to target
Overall win rate
38%
+ Follow
#2
Joseph Pantginis
HC Wainwright & Co. · Rank #373
Neutral
No targeton CAPR
Overall win rate
34%
+ Follow
#3
Leland Gershell
Oppenheimer · Rank #404
Buy
$54.00+572.1% to target
Overall win rate
35%
+ Follow
#4
Edward Tenthoff
Piper Sandler · Rank #460
Buy
$25.00+211.1% to target
Overall win rate
29%
+ Follow
#5
Jason McCarthy
Maxim Group · Rank #567
Neutral
No targeton CAPR
Overall win rate
30%
+ Follow
CAPR stock forecast FAQ
What is CAPR's average 12-month price target?+
The 6 active firms with a live target average $39.67 for Capricor Therapeutics Inc over the next 12 months, ranging from a $60.00 high to a $21.00 low, as of Nov 19, 2026.
Is CAPR stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 7 active firms as of Nov 19, 2026, 5 rate it Buy or Strong Buy, 2 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for CAPR?+
The Street-high target is $60.00, and the Street-low is $21.00 (B. Riley Securities). The average of all 6 active-firm targets is $39.67.
How many active Wall Street firms cover CAPR?+
7 active firms have a recognized rating on Capricor Therapeutics Inc as of Nov 19, 2026, and 6 active firms carry a live 12-month price target.
Who is the most accurate analyst covering CAPR?+
Among analysts who currently cover CAPR, Kristen Kluska of Cantor Fitzgerald has the strongest overall Quantellect track record (Rank #232). Their current call is Buy with a $28.00 target.
What is Capricor Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.46 per share (range $-0.61 – $-0.26) across 4 analysts. Full-year EPS is projected at $-2.45, rising to $-1.43 the following year.
How much revenue is Capricor Therapeutics Inc expected to report next quarter?+
Consensus revenue is $7.6M (range $0 – $18.7M). Full-year revenue is projected at $13.3M, growing to $66.4M next year.
Have analysts been upgrading or downgrading CAPR lately?+
As of Nov 19, 2026, 5 of 7 active firms rate CAPR a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CAPR calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.